KODIAK SCIENCES INC. Lessee, Operating Lease, Liability, to be Paid, Year One
KODIAK SCIENCES INC. (KOD) had Lessee, Operating Lease, Liability, to be Paid, Year One of $15.60 million as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2026-03-31
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $15.60M.
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $14.91M.
- 2023-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $14.79M.
- 2022-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $15.59M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2025-12-31 | $15.60M 10-K · filed 2026-03-31 |
| 2024-12-31 | $14.91M 10-K · filed 2025-03-27 |
| 2023-12-31 | $14.79M 10-K · filed 2024-03-28 |
| 2022-12-31 | $15.59M 10-K · filed 2023-03-28 |
| 2021-12-31 | $7.31M 10-K · filed 2022-03-01 |
| 2020-12-31 | $4.29M 10-K · filed 2021-03-01 |
| 2020-09-30 | $4.62M 10-Q · filed 2020-11-09 |
| 2019-12-31 | $533.00K 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |